The Experts below are selected from a list of 128931 Experts worldwide ranked by ideXlab platform
Mari Takashima - One of the best experts on this subject based on the ideXlab platform.
-
Relative Effectiveness of revaccination with 23 valent pneumococcal polysaccharide vaccine in preventing invasive pneumococcal disease in adult aboriginal and torres strait islander people australia
Vaccine, 2019Co-Authors: Mari Takashima, Stephen B Lambert, Stuart Paynter, Robert S WareAbstract:Abstract Background Aboriginal and Torres Strait Islander (Indigenous) Australians have high rates of invasive pneumococcal disease (IPD), with repeat doses of 23-valent polysaccharide pneumococcal vaccine (PPV23) recommended. We report the Relative Effectiveness of revaccination using a cohort from linked administrative data. Methods All resident North Queensland Indigenous adults who received any PPV23 vaccination between 2000 and 2012 were identified and linked with IPD cases. IPD rates were compared for individuals revaccinated >five years after initial PPV23 dose against individuals not revaccinated. Results Analysed data included 12,809 individuals and 89,612 person-years. Revaccinated adults had similar rates of IPD as non-revaccinated adults, after adjusting for potential confounders (HR = 0.92; 95%CI: 0.35–2.42). Findings were similar for vaccine-specific serotypes (HR = 1.32; 95%CI: 0.32–5.43). Conclusions Benefits of PPV23 revaccination against IPD in this high-risk population were not demonstrated, although estimates were imprecise. Findings should be validated in other high-risk cohorts, and against all-cause pneumonia as an outcome.
Robert S Ware - One of the best experts on this subject based on the ideXlab platform.
-
Relative Effectiveness of revaccination with 23 valent pneumococcal polysaccharide vaccine in preventing invasive pneumococcal disease in adult aboriginal and torres strait islander people australia
Vaccine, 2019Co-Authors: Mari Takashima, Stephen B Lambert, Stuart Paynter, Robert S WareAbstract:Abstract Background Aboriginal and Torres Strait Islander (Indigenous) Australians have high rates of invasive pneumococcal disease (IPD), with repeat doses of 23-valent polysaccharide pneumococcal vaccine (PPV23) recommended. We report the Relative Effectiveness of revaccination using a cohort from linked administrative data. Methods All resident North Queensland Indigenous adults who received any PPV23 vaccination between 2000 and 2012 were identified and linked with IPD cases. IPD rates were compared for individuals revaccinated >five years after initial PPV23 dose against individuals not revaccinated. Results Analysed data included 12,809 individuals and 89,612 person-years. Revaccinated adults had similar rates of IPD as non-revaccinated adults, after adjusting for potential confounders (HR = 0.92; 95%CI: 0.35–2.42). Findings were similar for vaccine-specific serotypes (HR = 1.32; 95%CI: 0.32–5.43). Conclusions Benefits of PPV23 revaccination against IPD in this high-risk population were not demonstrated, although estimates were imprecise. Findings should be validated in other high-risk cohorts, and against all-cause pneumonia as an outcome.
Jay D Amsterdam - One of the best experts on this subject based on the ideXlab platform.
-
Relative Effectiveness of monoamine oxidase inhibitor and tricyclic antidepressant combination therapy for treatment resistant depression
Journal of Clinical Psychopharmacology, 2019Co-Authors: Jay D Amsterdam, Thomas T KimAbstract:Purpose/background We examined the Relative safety and Effectiveness of adding a monoamine oxidase inhibitor (MAOI) to a failed tricyclic antidepressant (TCA) trial versus adding a TCA to a failed MAOI trial or adding a TCA to a failed TCA trial in treatment-resistant depression. Methods/procedures Data were retrospectively harvested from approximately 2500 treatment charts of subjects with treatment-resistant depression who attended a university mood disorders clinic between 1983 and 2015. Hierarchical linear modeling was used to examine the Effectiveness of treatment condition on outcome. Relative adverse event profiles were also examined. Findings/results Eighty-four treatment outcome observations were made from 54 subjects who received combination therapy: TCA plus TCA (n = 22), TCA plus MAOI (n = 44), and MAOI plus TCA (n = 18). Treatment condition predicted a poorer (albeit not statistically significant) outcome for TCA plus TCA compared with TCA plus MAOI, or MAOI plus TCA therapy (P = 0.098). Specific adverse events occurred with significantly greater frequency between treatment groups; that is, impotence was more frequent with TCA plus MAOI therapy; headaches and insomnia were more frequent with MAOI plus TCA therapy; and constipation was more frequent with TCA plus TCA therapy. There were no reported or observed hypertensive or serotonergic events. Implications/conclusions In contrast to conventional wisdom that combined TCA and MAOI therapy should be avoided, the judicious use of this combination may be Relatively safe and effective compared with combined TCA plus TCA therapy. However, sample sizes were limited, and the analysis was nonrandomized and retrospective.
-
Relative Effectiveness of tricyclic antidepressant versus monoamine oxidase inhibitor monotherapy for treatment resistant depression
Journal of Affective Disorders, 2019Co-Authors: Thomas T Kim, Jay D AmsterdamAbstract:Abstract Objectives Antidepressants may be less effective in treatment-resistant depression (TRD). In this exploratory study, we examined the widely held hypothesis that monoamine oxidase inhibitor (MAOI) therapy may be superior to tricyclic antidepressant (TCA) therapy for TRD. We also examined the influence of the number of prior treatment trials on TCA versus MAOI Effectiveness in TRD. Methods Data were retrospectively extracted from approximately 2,500 treatment charts of patients with TRD who were attending a university mood disorder clinic between 1983 and 2015. Hierarchical linear modeling was used to examine the efficacy of drug class on outcome as well as the interaction between drug class and the number of prior antidepressant trials. Results 147 treatment outcome observations were made from 94 unipolar, depressed patients who either received TCA (N = 47) or MAOI (N = 100) monotherapy for TRD. For patients unresponsive to at least one prior trial, drug class significantly predicted end-of-treatment CGI/S scores, with TCAs showing worse (i.e., higher) end-of-treatment CGI/S scores Relative to MAOI therapy (b = 1.04, t = 4.98, p Conclusion Results suggest that MAOIs may be more effective than TCAs for early stage TRD. This difference in Effectiveness between MAOIs and TCAs diminished as the number of prior treatment trials increased. However, the TCA sample size was limited and the analysis was retrospective with non-randomized conditions.
Thomas T Kim - One of the best experts on this subject based on the ideXlab platform.
-
Relative Effectiveness of monoamine oxidase inhibitor and tricyclic antidepressant combination therapy for treatment resistant depression
Journal of Clinical Psychopharmacology, 2019Co-Authors: Jay D Amsterdam, Thomas T KimAbstract:Purpose/background We examined the Relative safety and Effectiveness of adding a monoamine oxidase inhibitor (MAOI) to a failed tricyclic antidepressant (TCA) trial versus adding a TCA to a failed MAOI trial or adding a TCA to a failed TCA trial in treatment-resistant depression. Methods/procedures Data were retrospectively harvested from approximately 2500 treatment charts of subjects with treatment-resistant depression who attended a university mood disorders clinic between 1983 and 2015. Hierarchical linear modeling was used to examine the Effectiveness of treatment condition on outcome. Relative adverse event profiles were also examined. Findings/results Eighty-four treatment outcome observations were made from 54 subjects who received combination therapy: TCA plus TCA (n = 22), TCA plus MAOI (n = 44), and MAOI plus TCA (n = 18). Treatment condition predicted a poorer (albeit not statistically significant) outcome for TCA plus TCA compared with TCA plus MAOI, or MAOI plus TCA therapy (P = 0.098). Specific adverse events occurred with significantly greater frequency between treatment groups; that is, impotence was more frequent with TCA plus MAOI therapy; headaches and insomnia were more frequent with MAOI plus TCA therapy; and constipation was more frequent with TCA plus TCA therapy. There were no reported or observed hypertensive or serotonergic events. Implications/conclusions In contrast to conventional wisdom that combined TCA and MAOI therapy should be avoided, the judicious use of this combination may be Relatively safe and effective compared with combined TCA plus TCA therapy. However, sample sizes were limited, and the analysis was nonrandomized and retrospective.
-
Relative Effectiveness of tricyclic antidepressant versus monoamine oxidase inhibitor monotherapy for treatment resistant depression
Journal of Affective Disorders, 2019Co-Authors: Thomas T Kim, Jay D AmsterdamAbstract:Abstract Objectives Antidepressants may be less effective in treatment-resistant depression (TRD). In this exploratory study, we examined the widely held hypothesis that monoamine oxidase inhibitor (MAOI) therapy may be superior to tricyclic antidepressant (TCA) therapy for TRD. We also examined the influence of the number of prior treatment trials on TCA versus MAOI Effectiveness in TRD. Methods Data were retrospectively extracted from approximately 2,500 treatment charts of patients with TRD who were attending a university mood disorder clinic between 1983 and 2015. Hierarchical linear modeling was used to examine the efficacy of drug class on outcome as well as the interaction between drug class and the number of prior antidepressant trials. Results 147 treatment outcome observations were made from 94 unipolar, depressed patients who either received TCA (N = 47) or MAOI (N = 100) monotherapy for TRD. For patients unresponsive to at least one prior trial, drug class significantly predicted end-of-treatment CGI/S scores, with TCAs showing worse (i.e., higher) end-of-treatment CGI/S scores Relative to MAOI therapy (b = 1.04, t = 4.98, p Conclusion Results suggest that MAOIs may be more effective than TCAs for early stage TRD. This difference in Effectiveness between MAOIs and TCAs diminished as the number of prior treatment trials increased. However, the TCA sample size was limited and the analysis was retrospective with non-randomized conditions.
Stephen B Lambert - One of the best experts on this subject based on the ideXlab platform.
-
Relative Effectiveness of revaccination with 23 valent pneumococcal polysaccharide vaccine in preventing invasive pneumococcal disease in adult aboriginal and torres strait islander people australia
Vaccine, 2019Co-Authors: Mari Takashima, Stephen B Lambert, Stuart Paynter, Robert S WareAbstract:Abstract Background Aboriginal and Torres Strait Islander (Indigenous) Australians have high rates of invasive pneumococcal disease (IPD), with repeat doses of 23-valent polysaccharide pneumococcal vaccine (PPV23) recommended. We report the Relative Effectiveness of revaccination using a cohort from linked administrative data. Methods All resident North Queensland Indigenous adults who received any PPV23 vaccination between 2000 and 2012 were identified and linked with IPD cases. IPD rates were compared for individuals revaccinated >five years after initial PPV23 dose against individuals not revaccinated. Results Analysed data included 12,809 individuals and 89,612 person-years. Revaccinated adults had similar rates of IPD as non-revaccinated adults, after adjusting for potential confounders (HR = 0.92; 95%CI: 0.35–2.42). Findings were similar for vaccine-specific serotypes (HR = 1.32; 95%CI: 0.32–5.43). Conclusions Benefits of PPV23 revaccination against IPD in this high-risk population were not demonstrated, although estimates were imprecise. Findings should be validated in other high-risk cohorts, and against all-cause pneumonia as an outcome.
